Jane Street
AMLX icon

Jane Street’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jane Street’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$165K Buy
11,900
+1,800
+18% +$25.3K ﹤0.01% 10305
2025
Q4 		$122K Buy
+10,100
New +$137K ﹤0.01% 10070
2024
Q2 		– Sell
-78,100
Closed -$222K – 9277
2024
Q1 		$222K Sell
78,100
-1,865,000
-96% -$24.4M ﹤0.01% 8040
2023
Q4 		$28.6M Buy
1,943,100
+962,500
+98% +$14.8M 0.01% 998
2023
Q3 		$18M Buy
980,600
+6,400
+0.7% +$135K 0.01% 1192
2023
Q2 		$21M Buy
974,200
+318,000
+48% +$8.59M 0.01% 1163
2023
Q1 		$19.3M Buy
656,200
+33,900
+5% +$1.18M 0.01% 1039
2022
Q4 		$23M Buy
622,300
+317,400
+104% +$11.3M 0.01% 903
2022
Q3 		$8.58M Buy
304,900
+292,000
+2,264% +$7.28M ﹤0.01% 1858
2022
Q2 		$248K Buy
+12,900
New +$153K ﹤0.01% 7889

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Jane Street's AMLX Position: Q1 2026 in Review

Jane Street sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 263,235 shares — an estimated $3.7M sold.

Jane Street first reported a position in AMLX in Q1 2022 and held it in 14 quarters. The position peaked at $17M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Jane Street reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 263,235 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.7M.
  • Jane Street first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 14 quarters.
  • Jane Street's Amylyx Pharmaceuticals position peaked at $17M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.